MARKET WIRE NEWS

Future FinTech Signs Framework Agreement to Acquire TransGen SC Tech Limited Expanding into the Biomedical R&D Sector

MWN-AI** Summary

Future FinTech Group Inc. (NASDAQ: FTFT), a prominent player in financial and digital technology services, has announced a significant move into the biomedical research and development sector. On January 7, 2026, its wholly-owned subsidiary, Future FinTech (Hong Kong) Limited, entered into a Framework Agreement to acquire TransGen SC Tech Limited, a company specializing in biofactor R&D, for 100% of its shares. This acquisition is expected to be finalized within 90 days, pending due diligence and financial audits.

TransGen has established itself as a leader in biofactor research, focusing on therapeutic areas such as diabetes and Alzheimer's disease, and conducting research on microalgal extracellular vesicles for advanced drug delivery systems. With 26 invention patents and various certifications, TransGen also plays a pivotal role in setting industry standards for stem cell research and applications.

Gai Wei, Director of TransGen, expressed that this partnership with Future FinTech marks a vital step in their strategy to enhance international expansion and advance their technological innovations aimed at improving health and well-being.

Hu Li, CEO of FTFT, emphasized the strategic nature of this acquisition, noting that TransGen is well-positioned in a rapidly growing market due to demographic trends, including an aging population. He highlighted the potential for synergies between fintech capabilities and biomedical applications, particularly in creating innovative funding vehicles for medical-device initiatives.

This acquisition signals Future FinTech's commitment to diversifying its portfolio and tapping into the biomedical sector—a move that is expected to enhance shareholder value and promote technological advancements within TransGen's forte. The agreement showcases Future FinTech's ambition to leverage its digital finance proficiency to support the industrialization and commercialization of TransGen's groundbreaking technologies.

MWN-AI** Analysis

Future FinTech Group Inc. (NASDAQ: FTFT) recently announced a strategic move to diversify its operations by signing a Framework Agreement to acquire TransGen SC Tech Limited, a company specializing in biomedical research and development. This acquisition, aimed at expanding into the high-growth biomedical sector, is particularly timely given the increasing global focus on healthcare solutions driven by aging populations and rising healthcare expenditures.

From a market perspective, this acquisition can be seen as a significant favorable development for FTFT, positioning it in the burgeoning biofactor therapy market. The focus on diseases like diabetes and Alzheimer's, in conjunction with TransGen’s innovative research on microalgal extracellular vesicles, provides FTFT with a unique platform to explore lucrative product development avenues. The complexity of the biomedical sector requires not only cutting-edge technology but also stringent regulatory compliance, which TransGen has demonstrated through its numerous certifications and patents.

Investors should note the potential for FTFT to leverage its financial technology expertise in conjunction with TransGen's capabilities. The combination of risk modeling and capital market experience could enable FTFT to structure innovative financing solutions for biomedical initiatives, thus transforming R&D into viable marketable products. This synergy could enhance FTFT's value proposition in the healthcare space.

However, while the acquisition presents promising growth opportunities, investors should remain cautious. The successful integration of TransGen into FTFT's operations will depend on effective execution of due diligence and navigating the complexities of the biomedical landscape. Additionally, market volatility and regulatory risks could impact the realization of anticipated benefits.

In conclusion, FTFT's move into the biomedical sector through the acquisition of TransGen appears strategically sound and potentially lucrative. Investors may consider maintaining a close watch on developments to assess the long-term impact on FTFT’s market position and shareholder value.

**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.

Source: PR Newswire

Future FinTech Signs Framework Agreement to Acquire TransGen SC Tech Limited Expanding into the Biomedical R&D Sector

PR Newswire

NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Future FinTech a leading comprehensive financial and digital technology service provider, announced today that on January 7, 2026, its wholly-owned subsidiary, Future FinTech (Hong Kong) Limited ("FTFT HK"), signed a Framework Agreement (the "Agreement"), that outlines preliminary terms for its acquisition of 100% of the shares of TransGen SC Tech Limited ("TransGen").

Pursuant to the Agreement, the acquisition is expected to be completed within 90 calendar days subject to due diligence and a financial audit of TransGen. A formal acquisition agreement will be executed upon a satisfactory outcome, after which both parties will sign a definitive agreement.

TransGen has established a solid foundation in biofactor R&D, which entails processes that leverage naturally occurring compounds that support normal physiological functioning and that have health-promoting effects on disease prevention and overall wellness. TransGen's primary focus is on the high-value therapeutic areas of developing treatments for diabetes and Alzheimer's disease.

TransGen also conducts advanced research on the enrichment and functional properties of microalgal extracellular vesicles – naturally secreted nanoparticles from microalgae. These serve as next-generation nanocarriers for targeted drug delivery and diagnostics by harnessing their natural ability to transfer beneficial biological molecules. TransGen holds 26 invention patents and utility model patents. This includes numerous certifications and designations, including:

Level 2 Biosafety Laboratory Certification, which refers to standards and protocols for laboratories involved in moderate risk infectious agents, which is regulated by China's high-level National Health Commission.

Human Umbilical Cord Mesenchymal Stem Cells Qualification Certificate, that ensures the quality and safety of pharmaceuticals and biological products, issued by China's National Institutes for Food and Drug Control. 

TransGen has also played an instrumental role in the formulation of the group standard "Specification for Isolation and Preparation of Adipose-Derived Mesenchymal Stem Cells" and the local standard "Standards and Management Specifications for Human Mesenchymal Stem Cell Banks", underscoring its strong technological capabilities and recognized leadership within the industry.

Gai Wei, Director of TransGen, said, "TransGen focuses on technology R&D and industrialization in the biomedical field, possesses core technologies and compliance qualifications in areas such as biofactor therapy and microalgal extracellular vesicle research, and is committed to improving human health and well-being through biological innovation technologies. The signing of this agreement with Future Fintech marks a pivotal step for TransGen to partner with a globally resourced company to advance its international expansion strategy."

Hu Li, CEO of FTFT, stated, "The signing of this agreement represents our strategic plan to diversify into the biomedical sector since TransGen is poised for high growth and is well positioned in a large market driven by an aging population and rising healthcare spending. Further, our fintech capabilities in risk modeling, securitization and capital markets can be used to structure innovative funding vehicles for medical-device initiatives, turning biomedical R&D into investable products. We also see synergies for FTFT since secure identity, payments, and data sharing are critical in both finance and healthcare. This acquisition will help to promote the industrialization of TransGen technologies while delivering diversified long-term value for our shareholders."

About Future Fintech Group Inc.

Future FinTech Group Inc. (NASDAQ: FTFT) is a comprehensive financial and digital technology service provider. The Company, through its subsidiaries, conducts brokerage and investment banking services in Hong Kong, and engages in supply chain trading and finance businesses in China and efficient digital financial services. For more information, please visit www.ftft.com.

Safe Harbor Statement

Certain statements made in this press release are "forward-looking statements" within the meaning and protections of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Forward-looking statements include statements regarding our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions, and future performance, and involve known and unknown risks, uncertainties, and other factors that may be beyond our control, which may cause the actual results, performance, capital, ownership, or achievements of the Company to be materially different from those implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements by our use of words such as "may," "will," "anticipate," "assume," "should," "indicate," "would," "believe," "contemplate," "expect," "estimate," "continue," "plan," "point to," "project," "could," "intend," "target" and other similar words and expressions relating to the future.

 All written or oral forward-looking statements attributable to us are expressly qualified in their entirety by this cautionary notice, including, without limitation, the risks and uncertainties described in our annual report on Form 10-K for the year ended December 31, 2024 and our other reports and filings with the SEC. Such reports are available upon request from the Company, or from the Securities and Exchange Commission, including through the SEC's Internet website at http://www.sec.gov. We have no obligation and do not undertake to update, revise, or correct any of the forward-looking statements after the date hereof, or after the respective dates on which any such statements are otherwise made.

 

SOURCE Future FinTech Group Inc.

FAQ**

How does Future FinTech Group Inc. (FTFT) plan to integrate TransGen SC Tech Limited's biomedical R&D capabilities with its existing financial and digital technology services?

Future FinTech Group Inc. plans to integrate TransGen SC Tech Limited's biomedical R&D capabilities by leveraging its financial and digital technology services to enhance innovation, streamline operations, and create synergies between finance and healthcare sectors.

What specific potential synergies does FTFT foresee between its fintech expertise and TransGen's advancements in biomedical research?

FTFT anticipates leveraging its fintech expertise to enhance TransGen's biomedical research through improved data analytics, streamlined funding processes, and better financial management of research projects, ultimately accelerating innovation and commercialization in the biotech field.

Given the rigorous due diligence process involved, what risks does Future FinTech Group Inc. (FTFT) anticipate during the acquisition of TransGen SC Tech Limited?

Future FinTech Group Inc. (FTFT) anticipates risks related to integration challenges, potential regulatory hurdles, financial performance uncertainties, cultural alignment issues, and the overall impact of market fluctuations during the acquisition of TransGen SC Tech Limited.

In light of the aging population and rising healthcare spending, how does FTFT expect this acquisition to position it competitively within the biomedical market?

FTFT anticipates that this acquisition will enhance its competitive positioning in the biomedical market by leveraging advanced technologies and innovative solutions to cater to the growing demands of an aging population and escalating healthcare expenditures.

**MWN-AI FAQ is based on asking OpenAI questions about Future FinTech Group Inc. (NASDAQ: FTFT).

Future FinTech Group Inc.

NASDAQ: FTFT

FTFT Trading

-5.99% G/L:

$1.41 Last:

263 Volume:

$1.41 Open:

mwn-app Ad 300

FTFT Latest News

FTFT Stock Data

$8,430,708
4,336,514
3.14%
3
N/A
Software & IT Services
Technology
US
Causeway Bay

Subscribe to Our Newsletter

Link Market Wire News to Your X Account

Download The Market Wire News App